BioSpace News Archive

Shineco, Inc., a provider of innovative diagnostic medical products and related medical devices, announced that on June 20, 2024, the Company entered into a Securities Purchase Agreement with certain non-U.S. investors.

Helix, a leading population genomics company and provider of precision medicine genomics solutions, announced a groundbreaking multi-year agreement with Recursion Pharmaceuticals, a leading clinical-stage TechBio company decoding biology to industrialize drug discovery.

Revelation Biosciences Announces Phase 1 Clinical Study of Gemini Met the Primary Safety Endpoint and Showed Statistically Significant Biomarker Activity.

Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, today announced that it has filed for a type II variation of existing Marketing Authorization with the European Medicines Agency (EMA) for its JN.1 COVID-19 vaccine (NVX-CoV2705) for individuals aged 12 and older.

Hypha Labs, Inc. (OTC PINK:DIGP), a pioneer in functional mushroom sciences, is pleased to announce the addition of significant mycological innovations to its current patent portfolio.

Skinvisible Pharmaceuticals, Inc. (OTCQB:SKVI), an innovative topical / transdermal pharmaceutical research and development company, today announced the filing of a second patent application for its groundbreaking Invisicare® technology and its transdermal delivery of obesity and glucose-controlling agents.

CD Genomics, a renowned provider of genomics services, is pleased to announce the launch of its latest offering, Targeted Region Sequencing (TRS).

SOPHiA GENETICS SA is pleased to announce that its annual general meeting of shareholders was held at the Company’s headquarters, La Piece 12, 1180 Rolle/VD, Switzerland, earlier at 14:00 CEST.

Teva Pharmaceuticals, Inc., a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), announced today the launch of an authorized generic of Victoza®1 (liraglutide injection 1.8mg), in the United States.

The board of directors of Eli Lilly and Company has declared a dividend for the third quarter of 2024 of $1.30 per share on outstanding common stock.